Explore the Annual Scientific Meeting Advance Program!

HFSA Virtual AHFTC Board Certification Review 2022

August 12, 2022 - August 14, 2022 | Virtual

Faculty Disclosures

The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 24 months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.

Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.

The following faculty and/or accreditors with ability to control content for this activity have no conflict of interest:

  • Khadijah Breathett, MD, MS, FHFSA 
  • Brian Claggett, PhD 
  • Mark Drazner, MD, MSc, FHFSA 
  • Sadiya Khan, MD, MSc
  • Michelle Kittleson, MD, PHD 
  • Eric Krieger, MD 
  • Jon Lomasney, MD 
  • Jonathan Rich, MD, FHFSA
  • Joseph Rogers, MD 
  • Sanjiv Shah, MD
  • Nancy Sweitzer, MD, PhD, FHFSA

The following faculty and/or accreditors with ability to control content for this activity have listed the below disclosures:

  • Barry A. Borlaug, MD – Consultant: Amgen, Boehringer Ingelheim, Edwards LifeSciences, Merk, Novo Nordisk
  • Daniel Burkhoff, MD, PhD – Consultant: CardioDyme, ZOLL Medical; Research Support: Abiomed
  • Maria Rosa Costanzo, MD, FHFSA – Consultant: Nuwellis; Board Member: Nuwellis; Advisory Panel: Boehringer Ingeheim; Research Support: Abbott Laboratories, Novartis, V-Wave
  • Jennifer Cowger, MD, MS – Research Grant: Abbott Laboratories, Medtronic, Endotronix, Procyrion, Bivacor; Speaker/Honoraria: Abbott, Zoll, Bioventrix; Ownership/Interest: Procyrion; Consultant/Advisory Board: Abbott, Medtronic, Zoll, Endotronix, Procyrion, Bioventrix, Corware, Nuwellis, Bivacor
  • Akshay S. Desai, MD, MPH, FHFSA – Consultant: Abbott Laboratories, AstraZeneca, BayerAG, Novartis, Cytokinetics, DalCor Pharmaceuticals, GloaxoSmithKline, Merck, Relyspa, Regenron Pharmaceuticals, Verily, Biofourmis, Sun Pharmaceuticals, Lupin Pharmaceuticals, Avidity; Research Support: Abbott Laboratories, AstraZeneca, Bayer AG, Novartis, Alnylam Pharmaceuticals
  • James C. Fang, MD, FHFSA – Advisory Panel: Novartis, AstraZeneca, Amgen, Abbott Laboratories, ACI Clinical, Windtree Therapeutics, Boehringer Ingelheim 
  • Bonnie Ky, MD, MSCE  –  Consultant: Pfizer; IIS: Pfizer; Honorarium for Content: Uptodate; Echo Core Lab: Impulse Dynamics
  • Gregory Lewis, MD – Consultant: NXT
  • Sean Pinney, MD – Consultant: Abbott Laboratories, CareDX, Medtronic, Procyrion, TransMedics
  • Jeffrey Testani, MD, MTR – Consultant: 3ive labs, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Astra Zeneca, Novartis, Cardionomic, MagentaMed, Reprieve inc., FIRE1, W.L. Gore, Sanofi, Sequana Medical, Merck, Windtree Therapeutics, Lexicon pharmaceuticals, Precardia, Relypsa, Regeneron; Research Support: 3ive labs, Boehringer Ingelheim, Bristol Myers Squibb, Reprieve inc., FIRE1 Sanofi, Sequana Medical, Otsuka, Abbott, Merck; Stock Shareholder: Reprieve and Sequana
  • Roderick Tung, MD – Consultant: Boston Scientific, Medtronic, Abbott, Biotronik, Atricure
  • Wendy Tzou, MD – Consultant: Abbott, Biosense Webster, BioTel (Philips), BioSig, Boston Scientific, Medtronic; Speaker: Abbott, Biosense Webster, Biotronik, BioSig, Boston Scientific, Medtronic; Research: Abbott, Biosense Webster, Boston Scientific, Medtronic; Advisory Board: Biosense Webster, BioTel (Philips), Boston Scientific, Medtronic
  • Jane Wilcox, MD, MSc, FHFSA – Consultant: Abbott Laboratories; Advisory Panel: Abiomed, Cytokinetics; Speaker’s Bureau: Novartis

Off-Label Disclosure
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.